Submitted by Anonymous (not verified) on 6 February 2026 - 10:52
Human medicines European public assessment report (EPAR): Kisunla, donanemab, Date of authorisation: 24/09/2025, Revision: 2, Status: Authorised
Source:
Human medicines European public assessment report (EPAR): Kisunla, donanemab, Date of authorisation: 24/09/2025, Revision: 2, Status: Authorised